{"id":1861,"date":"2025-02-13T09:17:50","date_gmt":"2025-02-13T14:17:50","guid":{"rendered":"https:\/\/staging.arbor.bio\/?page_id=1861"},"modified":"2026-09-02T22:06:16","modified_gmt":"2026-09-03T02:06:16","slug":"clinical-trial","status":"publish","type":"page","link":"https:\/\/arbor.bio\/?page_id=1861","title":{"rendered":"Redefining Possibilities for Patients With Primary Hyperoxaluria Type 1 (PH1)"},"content":{"rendered":"","protected":false},"excerpt":{"rendered":"","protected":false},"author":9,"featured_media":0,"parent":0,"menu_order":3,"comment_status":"closed","ping_status":"closed","template":"page-sectional.php","meta":{"_acf_changed":false,"footnotes":""},"class_list":["post-1861","page","type-page","status-publish","hentry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Redefining Possibilities for Patients With Primary Hyperoxaluria Type 1 (PH1) - Arbor Biotechnologies<\/title>\n<meta name=\"description\" content=\"If you or a loved one has been diagnosed with Primary Hyperoxaluria Type 1, or PH1, learn more about the redePhine clinical trial and if you might be eligible for ABO-101.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/arbor.bio\/clinical-trial\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Redefining Possibilities for Patients With Primary Hyperoxaluria Type 1 (PH1) - Arbor Biotechnologies\" \/>\n<meta property=\"og:description\" content=\"If you or a loved one has been diagnosed with Primary Hyperoxaluria Type 1, or PH1, learn more about the redePhine clinical trial and if you might be eligible for ABO-101.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/arbor.bio\/clinical-trial\/\" \/>\n<meta property=\"og:site_name\" content=\"Arbor Biotechnologies\" \/>\n<meta property=\"article:modified_time\" content=\"2026-09-03T02:06:16+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/arbor.bio\\\/clinical-trial\\\/\",\"url\":\"https:\\\/\\\/arbor.bio\\\/clinical-trial\\\/\",\"name\":\"Redefining Possibilities for Patients With Primary Hyperoxaluria Type 1 (PH1) - Arbor Biotechnologies\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/arbor.bio\\\/#website\"},\"datePublished\":\"2025-02-13T14:17:50+00:00\",\"dateModified\":\"2026-09-03T02:06:16+00:00\",\"description\":\"If you or a loved one has been diagnosed with Primary Hyperoxaluria Type 1, or PH1, learn more about the redePhine clinical trial and if you might be eligible for ABO-101.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/arbor.bio\\\/clinical-trial\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/arbor.bio\\\/clinical-trial\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/arbor.bio\\\/clinical-trial\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/arbor.bio\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Redefining Possibilities for Patients With Primary Hyperoxaluria Type 1 (PH1)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/arbor.bio\\\/#website\",\"url\":\"https:\\\/\\\/arbor.bio\\\/\",\"name\":\"Arbor Biotechnologies\",\"description\":\"Our journey began at the genome.  It continues with the patient,\",\"publisher\":{\"@id\":\"https:\\\/\\\/arbor.bio\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/arbor.bio\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/arbor.bio\\\/#organization\",\"name\":\"Arbor Biotechnologies\",\"url\":\"https:\\\/\\\/arbor.bio\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/arbor.bio\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/arbor.bio\\\/wp-content\\\/uploads\\\/cropped-Transparent-Color-Logo.png\",\"contentUrl\":\"https:\\\/\\\/arbor.bio\\\/wp-content\\\/uploads\\\/cropped-Transparent-Color-Logo.png\",\"width\":1286,\"height\":1080,\"caption\":\"Arbor Biotechnologies\"},\"image\":{\"@id\":\"https:\\\/\\\/arbor.bio\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Redefining Possibilities for Patients With Primary Hyperoxaluria Type 1 (PH1) - Arbor Biotechnologies","description":"If you or a loved one has been diagnosed with Primary Hyperoxaluria Type 1, or PH1, learn more about the redePhine clinical trial and if you might be eligible for ABO-101.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/arbor.bio\/clinical-trial\/","og_locale":"en_US","og_type":"article","og_title":"Redefining Possibilities for Patients With Primary Hyperoxaluria Type 1 (PH1) - Arbor Biotechnologies","og_description":"If you or a loved one has been diagnosed with Primary Hyperoxaluria Type 1, or PH1, learn more about the redePhine clinical trial and if you might be eligible for ABO-101.","og_url":"https:\/\/arbor.bio\/clinical-trial\/","og_site_name":"Arbor Biotechnologies","article_modified_time":"2026-09-03T02:06:16+00:00","twitter_card":"summary_large_image","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/arbor.bio\/clinical-trial\/","url":"https:\/\/arbor.bio\/clinical-trial\/","name":"Redefining Possibilities for Patients With Primary Hyperoxaluria Type 1 (PH1) - Arbor Biotechnologies","isPartOf":{"@id":"https:\/\/arbor.bio\/#website"},"datePublished":"2025-02-13T14:17:50+00:00","dateModified":"2026-09-03T02:06:16+00:00","description":"If you or a loved one has been diagnosed with Primary Hyperoxaluria Type 1, or PH1, learn more about the redePhine clinical trial and if you might be eligible for ABO-101.","breadcrumb":{"@id":"https:\/\/arbor.bio\/clinical-trial\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/arbor.bio\/clinical-trial\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/arbor.bio\/clinical-trial\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/arbor.bio\/"},{"@type":"ListItem","position":2,"name":"Redefining Possibilities for Patients With Primary Hyperoxaluria Type 1 (PH1)"}]},{"@type":"WebSite","@id":"https:\/\/arbor.bio\/#website","url":"https:\/\/arbor.bio\/","name":"Arbor Biotechnologies","description":"Our journey began at the genome.  It continues with the patient,","publisher":{"@id":"https:\/\/arbor.bio\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/arbor.bio\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/arbor.bio\/#organization","name":"Arbor Biotechnologies","url":"https:\/\/arbor.bio\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/arbor.bio\/#\/schema\/logo\/image\/","url":"https:\/\/arbor.bio\/wp-content\/uploads\/cropped-Transparent-Color-Logo.png","contentUrl":"https:\/\/arbor.bio\/wp-content\/uploads\/cropped-Transparent-Color-Logo.png","width":1286,"height":1080,"caption":"Arbor Biotechnologies"},"image":{"@id":"https:\/\/arbor.bio\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/arbor.bio\/index.php?rest_route=\/wp\/v2\/pages\/1861","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/arbor.bio\/index.php?rest_route=\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/arbor.bio\/index.php?rest_route=\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/arbor.bio\/index.php?rest_route=\/wp\/v2\/users\/9"}],"replies":[{"embeddable":true,"href":"https:\/\/arbor.bio\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=1861"}],"version-history":[{"count":12,"href":"https:\/\/arbor.bio\/index.php?rest_route=\/wp\/v2\/pages\/1861\/revisions"}],"predecessor-version":[{"id":1986,"href":"https:\/\/arbor.bio\/index.php?rest_route=\/wp\/v2\/pages\/1861\/revisions\/1986"}],"wp:attachment":[{"href":"https:\/\/arbor.bio\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=1861"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}